Biotech | March 14, 2022
Clarivate deals report highlights emerging trends in biopharma deal-making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
The award recognizes and supports promising women scientists
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Subscribe To Our Newsletter & Stay Updated
